ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

ImmuCell Corporation (Nasdaq: ICCC), a pioneering animal health company dedicated to enhancing the health and productivity of dairy and beef cattle, has announced that its 2025 Annual Meeting of Stockholders will be conducted virtually on June 12, 2025, at 9:30 AM ET. This decision was previously communicated in the Proxy Statement filed with the SEC on April 24, 2025.

Participants can join the meeting via a telephone conference call or through a live audio webcast, with a listen-only option available for the webcast. Stockholders of record as of April 14, 2025, are encouraged to attend by dialing the provided numbers or accessing the webcast link. An informal Q&A session will follow the formal proceedings, but only participants on the telephone line can engage in this segment. For those unable to attend live, a recording of the meeting will be available for seven days post-event.

Stockholders are urged to vote and submit their proxies ahead of the meeting using the methods outlined in the proxy materials. For those wishing to vote during the meeting, prior arrangements must be made with the Company’s Voting Inspector. For insights into the Company’s performance, investors can review the recently filed Form 10-Q for the first quarter of 2025 and an updated Corporate Presentation on ImmuCell’s website.

ImmuCell is known for its innovative products, including First Defense®, which provides Immediate Immunity™ to newborn calves, and it is also advancing Re-Tain®, a unique treatment for subclinical mastitis in dairy cows that avoids issues associated with traditional antibiotics. More information about the Company can be found at their official website.

As ImmuCell Corporation (Nasdaq: ICCC) approaches its virtual-only Annual Meeting of Stockholders on June 12, 2025, investors should consider a hold position in the stock while closely monitoring key developments. The growing focus on enhancing animal health, specifically through scientifically proven products like First Defense® and potential breakthroughs like Re-Tain®, demonstrates ImmuCell's commitment to capturing market share within the dairy and beef cattle segments.

Given the shift to a virtual meeting format, stakeholders are reminded of the benefits of remote participation, including the accessibility of the informal Q&A session mainly conducted over the phone. Investors should utilize this opportunity to gather valuable insights directly from management regarding the company’s strategies for addressing challenges in the marketplace, particularly in relation to sustainable solutions in dairy production.

Financially, a review of the Q1 2025 report, particularly the revenue metrics and development statuses for current products, will be vital. The strong emphasis on innovation could set the stage for significant long-term growth; however, any potential delays in product launches or regulatory issues could pose risks.

While the current market conditions appear stable, the potential forthcoming decisions during the Annual Meeting could impact the stock’s trajectory. Investors should remain observant of voting outcomes, especially on matters pertinent to capital allocation and expansion strategies that may directly influence ImmuCell's growth prospects.

In summary, maintaining a hold on ImmuCell shares is prudent as investors await clearer signals regarding the company’s ongoing product development and strategic direction. Continued diligence in monitoring upcoming announcements and financial disclosures will be essential for making informed decisions moving forward.